U.S. Securities and Exchange Commission

Washington, D.C. 20549

____________________

FORM 8-K

____________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) February 11, 2013

 

____________________

 

Commission File No. 001-33718

____________________

 

Bioheart, Inc.

(Name of small business issuer as specified in its charter)

 

Florida

65-0945967

State of Incorporation

IRS Employer Identification No.

   

13794 NW 4th Street, Suite 212, Sunrise, Florida 33325

(Address of principal executive offices)

 

(954) 835-1500

(Issuer’s telephone number)

 

 



Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




In this Current Report on Form 8-K, “Company,” “our company,” “us,” and “our” refer to Bioheart, Inc., unless the context requires otherwise.

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On February 4, 2013, effective with the filing of the amendment to the Company's Articles of Incorporation with the Florida Secretary of State (confirmed as filed on February 11, 2013), the Company amended its Articles of Incorporation to increase the authorized shares of capital stock of the Company to nine hundred and seventy million (970,000,000) shares of capital stock consisting of nine hundred and fifty million (950,000,000) shares of common stock and twenty million (20,000,000) shares of preferred stock, both $.001 par value respectively.

 

Item 9.01 Financial Statements And Exhibits.

 

(d) Exhibits:

 

3.1

Articles of Amendment to the Articles of Incorporation of the Company, incorporated by reference to the Company Definitive Information Statement on Schedule 14C, filed with the Securities and Exchange Commission on January 7, 2013.

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Registrant

Date: February 11, 2013

 

 

Bioheart, Inc.

By: /s/ Mike Tomas

    Mike Tomas
    Chief Executive Officer